NO20043246L - Nye fremgangsmater til diagnose og behandling av tumorer - Google Patents

Nye fremgangsmater til diagnose og behandling av tumorer

Info

Publication number
NO20043246L
NO20043246L NO20043246A NO20043246A NO20043246L NO 20043246 L NO20043246 L NO 20043246L NO 20043246 A NO20043246 A NO 20043246A NO 20043246 A NO20043246 A NO 20043246A NO 20043246 L NO20043246 L NO 20043246L
Authority
NO
Norway
Prior art keywords
tumors
diagnosis
treatment
new methods
new
Prior art date
Application number
NO20043246A
Other languages
English (en)
Norwegian (no)
Inventor
Christoph-Stephan Hilger
Ludger Dinkelborg
Giovanni Neri
Dieter Moosmayer
Dietmar Berndorff
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20043246L publication Critical patent/NO20043246L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20043246A 2002-01-03 2004-08-02 Nye fremgangsmater til diagnose og behandling av tumorer NO20043246L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02000315 2002-01-03
US35870202P 2002-02-25 2002-02-25
PCT/EP2003/000009 WO2003055917A2 (en) 2002-01-03 2003-01-02 Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours

Publications (1)

Publication Number Publication Date
NO20043246L true NO20043246L (no) 2004-08-02

Family

ID=26077560

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043246A NO20043246L (no) 2002-01-03 2004-08-02 Nye fremgangsmater til diagnose og behandling av tumorer

Country Status (14)

Country Link
US (1) US20040001790A1 (ru)
EP (2) EP2239274A1 (ru)
JP (2) JP2005523887A (ru)
CN (1) CN1612895B (ru)
AU (1) AU2003210149B2 (ru)
BR (1) BR0306715A (ru)
CA (1) CA2468081A1 (ru)
CY (1) CY1110923T1 (ru)
IL (2) IL162201A0 (ru)
MX (1) MXPA04006517A (ru)
NO (1) NO20043246L (ru)
PL (1) PL369371A1 (ru)
RU (1) RU2352582C2 (ru)
WO (1) WO2003055917A2 (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9610967D0 (en) * 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
AU4243201A (en) 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
PL364358A1 (en) * 2000-09-07 2004-12-13 Schering Ag Receptor in the edb fibronectin domain (ii)
JP2005534283A (ja) * 2002-03-11 2005-11-17 フィロジェン ソチエタ ペル アツィオニ 抗体分子を用いての腫瘍脈管系の選択的標的化
EP1514561A1 (en) * 2003-09-10 2005-03-16 Philogen S.p.A. Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B
DE10348319A1 (de) * 2003-10-17 2005-05-19 Schering Ag Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques
US20060039863A1 (en) * 2004-07-22 2006-02-23 Michael Schirner Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
EP1619501B1 (en) * 2004-07-22 2007-09-26 Bayer Schering Pharma Aktiengesellschaft Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
ES2291071B1 (es) * 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. Agentes y metodos basados en el uso del dominio eda de la fibronectina.
EP2015775B1 (en) * 2006-05-03 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
JP5221641B2 (ja) * 2007-04-02 2013-06-26 フィロゲン エスピーエー 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原
EP2036576A1 (en) * 2007-09-17 2009-03-18 Bayer Schering Pharma Aktiengesellschaft ED-B fibronectin as stratification marker for antitumor drugs
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
EP2116555A1 (en) 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
US9603954B2 (en) 2009-07-22 2017-03-28 Actinium Pharmaceuticals Inc. Methods for generating radioimmunoconjugates
JP5892540B2 (ja) * 2009-12-25 2016-03-23 国立研究開発法人理化学研究所 生体内にて標的組織に指向する放射標識化合物およびその利用
WO2011110490A1 (en) 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft Process for the production of radioactively labelled scfv antibody fragments, kits and compositions
CN104215668A (zh) * 2014-08-25 2014-12-17 浙江大学 基于theed纤维阵列的二氧化碳传感器及其制备方法
WO2017084017A1 (zh) * 2015-11-16 2017-05-26 合肥立方制药股份有限公司 Ed-b蛋白在诊断组织增生中的应用
EP3525828B1 (en) * 2016-10-17 2024-12-25 Pfizer Inc. Anti-edb antibodies and antibody-drug conjugates
US12569577B2 (en) * 2019-10-29 2026-03-10 The Cleveland Clinic Foundation PSMA-targeting imaging agents
HRP20241274T1 (hr) 2020-05-22 2024-12-06 Philogen S.P.A. Terapija na bazi tnf-a imunokonjugata za liječenje tumora mozga
AU2022310862A1 (en) 2021-07-14 2024-02-01 Regeneron Pharmaceuticals, Inc. Engineered t cell receptors fused to binding domains from antibodies
IL316032A (en) 2022-04-08 2024-11-01 Regeneron Pharma Multicomponent receptor and signaling complexes
WO2025058000A1 (ja) 2023-09-13 2025-03-20 東レ株式会社 癌の治療、予防及び／又は診断用医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3070763B2 (ja) * 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
WO1993016185A2 (en) * 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US6171578B1 (en) * 1999-04-14 2001-01-09 Diatide, Inc. Benzodiazepine derivatives for imaging thrombi
IL145941A (en) * 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
AU4243201A (en) 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis

Also Published As

Publication number Publication date
EP2239274A1 (en) 2010-10-13
JP4663020B2 (ja) 2011-03-30
BR0306715A (pt) 2004-12-28
CN1612895B (zh) 2010-05-12
CA2468081A1 (en) 2003-07-10
CY1110923T1 (el) 2015-06-10
EP1461360A2 (en) 2004-09-29
RU2352582C2 (ru) 2009-04-20
HK1076474A1 (zh) 2006-01-20
WO2003055917A2 (en) 2003-07-10
MXPA04006517A (es) 2005-03-31
CN1612895A (zh) 2005-05-04
RU2004123785A (ru) 2005-08-10
EP1461360B1 (en) 2010-08-18
IL162201A0 (en) 2005-11-20
AU2003210149A1 (en) 2003-07-15
JP2009209149A (ja) 2009-09-17
AU2003210149B2 (en) 2008-10-09
WO2003055917A3 (en) 2003-12-24
US20040001790A1 (en) 2004-01-01
IL162201A (en) 2011-04-28
JP2005523887A (ja) 2005-08-11
PL369371A1 (en) 2005-04-18

Similar Documents

Publication Publication Date Title
DK1587837T3 (da) Epitopsekvenser til diagnose og behandling af prostatacancer
NO20023402D0 (no) Blandinger og fremgangsmåter for behandling og diagnose av prostatakreft
NO20034020D0 (no) Nye MHC molekylforbindelser, og metoder for anvendelse av disse forbindelsene for diagnose og terapi, og anvendelse av MHC molekyler
NO20030714L (no) Blandinger og fremgangsmåter for behandling og diagnose av HER-2/NEU-assosierte maligniteter
DK1530724T3 (da) Diagnose og forebyggelse af cancercelleinvasion
NO20014769D0 (no) Preparat for behandling og diagnose av bryst cancer og fremgangsmåter for anvendelse derav
DE602004021618D1 (de) Diagnostische testvorrichtung und anwendungsverfahren dafür
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
NO20013002L (no) Blandinger og fremgangsmåter for behandling og diagnose av ovariekreft
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
IS7684A (is) Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
DE60332649D1 (de) Mehrlumige struktur für eine implantierbare medizinische vorrichtung
DE602004024630D1 (de) Ultraschalldiagnosegerät
FI20030598L (fi) Mittalaite ja menetelmä sykkeen mittaamiseksi sekä mittalaitteen valmistusmenetelmä
DE602004023991D1 (de) Ultraschalldiagnosegerät
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
IL165950A0 (en) Compositions and method for the diagnosis and treatment of tumor
IL162201A0 (en) New methods for diagnosis and treatment of tumours
PL374898A1 (pl) Metoda ulepszonej diagnostyki dysplazji
NO20024972L (no) Blandinger og fremgangsmater for terapi og diagnose av brystkreft
DE60308431D1 (de) Geschäumte Säurebehandlungsflüssigkeit
DE60308985D1 (de) Ultraschallabbildungsgerät und Methode
ZA200510282B (en) Compositions and methods for the diagnosis and treatment of tumor
NO20053874D0 (no) Formulering og metoder for behandling av thrombocytemi
IS8497A (is) Aðferðir og hvarfefni til að meðhöndla bólgusjúkdóma